Business
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement (the “Agreement”) with E
About this update from Candel Therapeutics, Inc.
[{"type":"image","alt":"Candel Therapeutics","displaySize":"","headline":null,"caption":"Candel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":137,"url":"https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.UDl8bhJsgxnqpejVYBG6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mg--/https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe","width":300,"height":137}},"lazy":false},{"type":"text","content":"EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026","length":161,"tagName":"p"},{"type":"text","content":"NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement (the “Agreement”) with EVERSANA®, a leading provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer.","length":613,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, EVERSANA will provide Candel with a broad suite of integrated commercialization services including data and analytics, medical affairs, market access and field operations. EVERSANA joins IDEA Pharma, a division of SAI MedPartners (IDEA), which has been providing path-to-market strategies and strategic positioning for aglatimagene. Candel has worked in close collaboration with both EVERSANA and IDEA on key pre-commercial workstreams as previously announced during Candel’s virtual Research and Development Day in December 2025.","length":564,"tagName":"p"},{"type":"text","content":"This collaboration reflects Candel’s deliberate approach to building a world class commercial organization with global reach, designed from the ground up and leveraging a team of highly experienced professionals poised to support the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prost...